The company could earn up to $43 million from its collaboration with Fujifilm Corp, which gave the Japanese firm rights to CYP-001 in graft-versus-host disease, a complication that occurs after bone marrow transplants.

Cash from the deal will help Cynata’s cash runway and support further investment in the upcoming Phase II trials in critical limb ischemia and in osteoarthritis, along with other potential future clinical programs.